SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Zetterberg H) "

Sökning: WFRF:(Zetterberg H)

  • Resultat 61-70 av 401
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Johnsson, Magnus, 1983, et al. (författare)
  • Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study
  • 2024
  • Ingår i: MULTIPLE SCLEROSIS JOURNAL. - 1352-4585 .- 1477-0970. ; 30:6, s. 664-673
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS). However, the diagnostic properties of sNfL for monitoring disease activity in individual patients warrant further investigations. Method: Patients with suspected relapse and/or contrast-enhancing lesions (CELs) were consecutively included and performed magnetic resonance imaging (MRI) of the brain at baseline and weeks 28 and 48. Serum was obtained at baseline and 2, 4, 8, 16, 24, and 48 weeks. Neurofilament light concentration was measured using Single molecule array technology. Results: We included 44 patients, 40 with RRMS and 4 with clinically isolated syndrome. The median sNfL level peaked at 2 weeks post-baseline (14.6 ng/L, interquartile range (IQR); 9.3-31.6) and reached nadir at 48 weeks (9.1 ng/L, IQR; 5.5-15.0), equivalent to the median sNfL of controls (9.1 ng/L, IQR; 7.4-12). A baseline Z-score of more than 1.1 (area under the curve; 0.78, p < 0.0001) had a sensitivity of 81% and specificity of 70% to detect disease activity. Conclusion: One out of five patients with relapse and/or CELs did not change significantly in post-baseline sNfL levels. The utility of repeated sNfL measurements to monitor disease activity is complementary rather than a substitute for clinical and MRI measures.
  •  
62.
  •  
63.
  • Keshavan, A., et al. (författare)
  • Concordance of csf measures of alzheimer’s pathology with amyloid pet status in a preclinical cohort: A comparison of lumipulse and established immunoassays
  • 2021
  • Ingår i: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. - : Wiley. - 2352-8729. ; 13:1
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with presymptomatic Alzheimer’s disease (AD) pathology on amyloid positron emission tomography (PET). METHODS: In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t-tau), and phosphorylated tau at site 181 (p-tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter-platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut-points optimizing concordance with18F florbetapir amyloid PET status (n = 63). RESULTS: Measurements of CSF Aβ, p-tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P < .0001); those of t-tau and t-tau/Aβ42 correlated moderately (r 0.57 to 0.79, P < .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut-points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p-tau181. DISCUSSION: The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology. © 2020 The Authors.
  •  
64.
  • Kleinberger, G., et al. (författare)
  • TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
  • 2014
  • Ingår i: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 6:243
  • Tidskriftsartikel (refereegranskat)abstract
    • Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to Nasu-Hakola disease, Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and FTD-like syndrome without bone involvement. TREM2 is an innate immune receptor preferentially expressed by microglia and is involved in inflammation and phagocytosis. Whether and how TREM2 missense mutations affect TREM2 function is unclear. We report that missense mutations associated with FTD and FTD-like syndrome reduce TREM2 maturation, abolish shedding by ADAM proteases, and impair the phagocytic activity of TREM2-expressing cells. As a consequence of reduced shedding, TREM2 is virtually absent in the cerebrospinal fluid (CSF) and plasma of a patient with FTD-like syndrome. A decrease in soluble TREM2 was also observed in the CSF of patients with AD and FTD, further suggesting that reduced TREM2 function may contribute to increased risk for two neurodegenerative disorders.
  •  
65.
  • Lagebrant, Alice, et al. (författare)
  • Brain injury markers in blood associate with generalised oedema on computed tomography after cardiac arrest
  • 2021
  • Ingår i: - : Springer Science and Business Media LLC. ; , s. 203-204
  • Konferensbidrag (refereegranskat)abstract
    • Introduction. According to the 2021 ERC/ESICM guideline recommen-dations, elevated neuron-specific enolase [NSE] levels as well as diffuseand extensive anoxic damage on neuroimaging are predictors of poorneurological outcome after cardiac arrest.(1) We previously describedthat NSE is elevated in patients with generalised oedema on com-puted tomography [CT]. (2).Objectives. In this study, we aim to examine the novel brain injurymarkers serum neurofilament light [NFL], glial fibrillary acidic protein[GFAP] and total-tau [tau] to predict the presence of generalised brainoedema.Methods. Retrospective analysis of patients examined with CT onclinical indication within the Target Temperature Management afterout-of-hospital cardiac arrest [TTM] trial. (2,3) Serum samples fromthe biobank sub study were prospectively collected at 48 h post arrestand analysed after trial completion as published. (4–7) The neuronalmarker NSE, the neuroaxonal injury markers NFL and tau and theastrocytic injury marker GFAP were correlated with the presence ofgeneralised oedema on CT, assessed by local radiologists through vis-ual evaluation. The prognostic accuracy of NSE ≥ 60 ug/l for predictinggeneralised oedema was also analysed.Results. 192 patients had data available on all four biomarkers at 48 hand were examined with CT < 168 h post arrest. Brain injury markerswere significantly higher in patients with generalised oedema as com-pared to patients without oedema on CT scans performed 24–168 hafter ROSC (p < 0.001) (Fig. 1A–D). For CT scans performed < 24 h, onlyNSE levels showed a significant correlation (p < 0.05). Biomarkers pre -dicted generalised oedema with area under the receiver operatingcharacteristics curve [AUC] 67.5–73.2% for CT scans performed < 24 h(n = 111), with no statistically significant difference between themarkers ( Fig. 2A). For scans performed 24–168 h (n = 81) AUC for pre -dicting generalised oedema was 78.1%-82.9%, with no statisticallysignificant difference between the markers. NSE ≥ 60 ug/l at 48 h, asrecommended by guidelines, predicted generalised oedema with 81%(95%CI 67–90%) sensitivity and 77% (95%CI 62–87%) specificity.Conclusion. Concentrations of all evaluated brain injury markerswere significantly higher in patients with generalised oedema on CTperformed after the first 24 h post arrest. Biomarker concentrationsindicate whether generalised oedema on CT is likely and may thus beclinically useful for deciding if a CT scan is sufficient for prognostica-tion or if a MRI is more appropriate.
  •  
66.
  • Lauwers, E., et al. (författare)
  • Potential human transmission of amyloid beta pathology: surveillance and risks
  • 2020
  • Ingår i: Lancet Neurology. - 1474-4422 .- 1474-4465. ; 19:10, s. 872-878
  • Tidskriftsartikel (refereegranskat)abstract
    • Studies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Although these data raise potential concerns for public health, convincing evidence for human iatrogenic transmission only exists for prions and amyloid beta after systemic injections of contaminated growth hormone extracts or dura mater grafts derived from cadavers. Even though these procedures are now obsolete, some reports raise the possibility of iatrogenic transmission of amyloid beta through putatively contaminated neurosurgical equipment. Iatrogenic transmission of amyloid beta might lead to amyloid deposition in the brain parenchyma and blood vessel walls, potentially resulting in cerebral amyloid angiopathy after several decades. Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid can also lead to Alzheimer's dementia. Large, long-term epidemiological studies and sensitive, cost-efficient tools to detect amyloid are needed to better understand any potential routes of amyloid beta transmission and to clarify whether other similar proteopathic seeds, such as tau or alpha-synuclein, can also be transferred iatrogenically.
  •  
67.
  • Lista, S., et al. (författare)
  • Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline
  • 2015
  • Ingår i: Journal of Alzheimers Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 48
  • Tidskriftsartikel (refereegranskat)abstract
    • There is evolving evidence that individuals categorized with subjective cognitive decline (SCD) are potentially at higher risk for developing objective and progressive cognitive impairment compared to cognitively healthy individuals without apparent subjective complaints. Interestingly, SCD, during advancing preclinical Alzheimer's disease (AD), may denote very early, subtle cognitive decline that cannot be identified using established standardized tests of cognitive performance. The substantial heterogeneity of existing SCD-related research data has led the Subjective Cognitive Decline Initiative (SCD-I) to accomplish an international consensus on the definition of a conceptual research framework on SCD in preclinical AD. In the area of biological markers, the cerebrospinal fluid signature of AD has been reported to be more prevalent in subjects with SCD compared to healthy controls; moreover, there is a pronounced atrophy, as demonstrated by magnetic resonance imaging, and an increased hypometabolism, as revealed by positron emission tomography, in characteristic brain regions affected by AD. In addition, SCD individuals carrying an apolipoprotein epsilon 4 allele are more likely to display AD-phenotypic alterations. The urgent requirement to detect and diagnose AD as early as possible has led to the critical examination of the diagnostic power of biological markers, neurophysiology, and neuroimaging methods for AD-related risk and clinical progression in individuals defined with SCD. Observational studies on the predictive value of SCD for developing AD may potentially be of practical value, and an evidence-based, validated, qualified, and fully operationalized concept may inform clinical diagnostic practice and guide earlier designs in future therapy trials.
  •  
68.
  • Lu, H. Y., et al. (författare)
  • DiLeu Isobaric Labeling Coupled with Limited Proteolysis Mass Spectrometry for High-Throughput Profiling of Protein Structural Changes in Alzheimer's Disease
  • 2023
  • Ingår i: Analytical Chemistry. - 0003-2700. ; 95:26, s. 9746-9753
  • Tidskriftsartikel (refereegranskat)abstract
    • High-throughput quantitative analysis of protein conformationalchanges has a profound impact on our understanding of the pathologicalmechanisms of Alzheimer's disease (AD). To establish an effectiveworkflow enabling quantitative analysis of changes in protein conformationwithin multiple samples simultaneously, here we report the combinationof N,N-dimethyl leucine (DiLeu) isobaric tag labelingwith limited proteolysis mass spectrometry (DiLeu-LiP-MS) for high-throughputstructural protein quantitation in serum samples collected from ADpatients and control donors. Twenty-three proteins were discoveredto undergo structural changes, mapping to 35 unique conformotypicpeptides with significant changes between the AD group and the controlgroup. Seven out of 23 proteins, including CO3, CO9, C4BPA, APOA1,APOA4, C1R, and APOA, exhibited a potential correlation with AD. Moreover,we found that complement proteins (e.g., CO3, CO9, and C4BPA) relatedto AD exhibited elevated levels in the AD group compared to thosein the control group. These results provide evidence that the establishedDiLeu-LiP-MS method can be used for high-throughput structural proteinquantitation, which also showed great potential in achieving large-scaleand in-depth quantitative analysis of protein conformational changesin other biological systems.
  •  
69.
  • Malek-Ahmadi, M., et al. (författare)
  • Plasma NfL is associated with the APOE epsilon 4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults
  • 2023
  • Ingår i: Alzheimer's Research & Therapy. - 1758-9193. ; 15:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer's disease (AD) and a wide range of other neurological disorders. Here, we characterized and compared plasma NfL concentrations in cognitively unimpaired (CU) late-middle-aged and older adults with two, one, or no copies of the APOE epsilon 4 allele, the major genetic risk factor for AD. We then assessed plasma NfL associations with brain imaging measurements of AD-related neurodegeneration (hippocampal atrophy and a hypometabolic convergence index [HCI]), brain imaging measurements of amyloid-beta plaque burden, tau tangle burden and white matter hyperintensity volume (WMHV), and delayed and total recall memory scores. Methods Plasma NfL concentrations were measured in 543 CU 69 +/- 9 year-old participants in the Arizona APOE Cohort Study, including 66 APOE epsilon 4 homozygotes (HM), 165 heterozygotes (HT), and 312 non-carriers (NC). Robust regression models were used to characterize plasma NfL associations with APOE epsilon 4 allelic dose before and after adjustment for age, sex, and education. They were also used to characterize plasma NfL associations with MRI-based hippocampal volume and WMHV measurements, an FDG PET-based HCI, mean cortical PiB PET measurements of amyloid-beta plaque burden and meta-region-of-interest (meta-ROI) flortaucipir PET measurements of tau tangle burden, and Auditory Verbal Learning Test (AVLT) Delayed and Total Recall Memory scores. Results After the adjustments noted above, plasma NfL levels were significantly greater in APOE epsilon 4 homozygotes and heterozygotes than non-carriers and significantly associated with smaller hippocampal volumes (r = - 0.43), greater tangle burden in the entorhinal cortex and inferior temporal lobes (r = 0.49, r = 0.52, respectively), and lower delayed (r = - 0.27), and total (r = - 0.27) recall memory scores (p < 0.001). NfL levels were not significantly associated with PET measurements of amyloid-beta plaque or total tangle burden. Conclusions Plasma NfL concentrations are associated with the APOE epsilon 4 allele, brain imaging biomarkers of neurodegeneration, and less good recall memory in CU late-middle-aged and older adults, supporting its value as an indicator of neurodegeneration in the preclinical study of AD.
  •  
70.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 401
Typ av publikation
tidskriftsartikel (344)
konferensbidrag (44)
forskningsöversikt (6)
rapport (3)
bokkapitel (3)
bok (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (347)
övrigt vetenskapligt/konstnärligt (54)
Författare/redaktör
Zetterberg, Henrik, ... (281)
Blennow, Kaj, 1958 (183)
Zetterberg, H. (84)
Blennow, K (65)
Hansson, Oskar (23)
Ashton, Nicholas J. (18)
visa fler...
Andreasson, Ulf, 196 ... (18)
Scheltens, P (17)
Wallin, Anders, 1950 (16)
Portelius, Erik, 197 ... (15)
Teunissen, Charlotte ... (15)
Heslegrave, A. (15)
Lleó, A. (14)
Schott, J. M. (12)
Gobom, Johan (12)
Skoog, Ingmar, 1954 (11)
Tsolaki, M (11)
Kern, Silke (11)
Zettergren, Anna, 19 ... (11)
Molinuevo, J. L. (11)
Vanderstichele, H (11)
Aarsland, D (10)
Vandenberghe, R (10)
Piehl, F (10)
Soininen, H (10)
Herukka, S K (10)
Dubois, B (10)
Scheltens, Philip (10)
Karikari, Thomas (10)
Andreasen, N (10)
Vanmechelen, E (10)
Minthon, Lennart (9)
Landen, M (9)
Hardy, J (9)
Lovestone, S (9)
Lleó, Alberto (9)
Engelborghs, Sebasti ... (9)
Kivipelto, M (8)
Winblad, B (8)
Axelsson, M. (8)
Olsson, T (8)
Sellgren, C (8)
Brinkmalm, Gunnar (8)
Skoog, I (8)
Janelidze, Shorena (8)
Stomrud, Erik (8)
van der Flier, Wiesj ... (8)
Fortea, Juan (8)
Alcolea, D. (8)
Fortea, J. (8)
visa färre...
Lärosäte
Göteborgs universitet (293)
Karolinska Institutet (129)
Lunds universitet (46)
Uppsala universitet (20)
Örebro universitet (12)
Linköpings universitet (7)
visa fler...
Umeå universitet (6)
Kungliga Tekniska Högskolan (6)
Stockholms universitet (5)
Luleå tekniska universitet (4)
Jönköping University (3)
Chalmers tekniska högskola (3)
Högskolan i Gävle (2)
Mälardalens universitet (1)
Malmö universitet (1)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (398)
Svenska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (320)
Naturvetenskap (8)
Teknik (6)
Samhällsvetenskap (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy